Related Experiment Video
Updated: Jul 7, 2026
14:20
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
LHRH receptor targeted therapy for breast cancer
1Department of Medicine and James Graham Brown Cancer Center, University of Louisville, Louisville, KY 40202, USA.
Advances in Experimental Medicine and Biology
|February 23, 2008
Summary
Targeted nanoparticles show promise for breast cancer treatment. Iron oxide nanoparticles conjugated with LHRH analogs effectively killed breast cancer cells, offering a potential new therapy.
Area of Science:
- Oncology
- Nanomedicine
- Biotechnology
Background:
- Breast cancer is a leading cause of death among women globally.
- Luteinizing hormone-releasing hormone (LHRH) receptors are overexpressed in various cancer cells, including breast cancer.
- Targeting LHRH receptors offers a potential strategy for cancer therapy due to their limited expression in healthy tissues.
Purpose of the Study:
- To investigate the efficacy of iron oxide nanoparticles conjugated with [D-Trp6]LHRH (Triptorelin) for targeted breast cancer therapy.
- To evaluate the impact of these targeted nanoparticles on breast cancer cell lines (MCF-7 and MDA-MB231).
Main Methods:
- Synthesis and characterization of Fe3O4 nanoparticles (20-30 nm) conjugated with [D-Trp6]LHRH.
- Assessment of the binding affinity and biological activity of the conjugated nanoparticles.
- Treatment of MCF-7 and MDA-MB231 breast cancer cell lines with the conjugated nanoparticles and control substances.
Main Results:
- Conjugation of [D-Trp6]LHRH to Fe3O4 nanoparticles preserved its receptor binding affinity and biological activity.
- Treatment with the conjugated nanoparticles resulted in 95-98% cell death and loss of viability in breast cancer cell lines within 24 hours.
- No significant changes in cell proliferation or apoptosis were observed with unconjugated Fe3O4 nanoparticles or free [D-Trp6]LHRH.
Conclusions:
- LHRH receptor-targeted iron oxide nanoparticles demonstrate potent and selective cytotoxicity against breast cancer cells.
- This targeted nanoparticle approach holds significant potential as a novel therapeutic strategy for breast cancer treatment.
- Further research into LHRH receptor-targeted therapies could lead to more effective and less toxic cancer treatments.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:31Transducer Mechanism: Nuclear Receptors
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...